ストックスクリーナーアプリを入手
3.70
1.93%
0.07
アフターアワーズ：
3.70
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
Budget pitch: Pharma Inc seeks tax breaks for research and development - The Economic Times
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Tarsus Pharmaceuticals, Inc. $TARS Shares Purchased by Jennison Associates LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
Telehealth deal lets U.S. travelers secure weekly malaria prevention pre-trip - Stock Titan
31,152 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Rakuten Investment Management Inc. - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Aug Breakouts: What is the long term forecast for X4 Pharmaceuticals Inc stockJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Pfizer Inc. - Britannica
Lilly, Takeda targeted by legal strategy usually reserved for the mob - Pharma Voice
Corvus eczema drug improves key symptoms for 75% in early trial - Stock Titan
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Value Investment Case - Chartmill
Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever - The Economic Times
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by ASR Vermogensbeheer N.V. - MarketBeat
Layoff Tracker: Takeda Slashes US Headcount, Hitting Neuro Commercial Teams Hard - BioSpace
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are individual investors with 52% ownership, institutions own 31% - Yahoo Finance
Quarterly Trades: Is AXSPRE attractive at current valuationWeekly Gains Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by PGGM Investments - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC - MarketBeat
Nasdaq-listed 60 Degrees Pharma shrinks shares 4-for-1 on Jan. 20 reverse - Stock Titan
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Could Be Riskier Than It Looks - simplywall.st
Market Recap: What Wall Street predicts for X4 Pharmaceuticals Inc stock priceBear Alert & Accurate Buy Signal Alerts - Bộ Nội Vụ
Gains Report: How X4 Pharmaceuticals Inc stock reacts to inflationary pressuresM&A Rumor & Consistent Profit Trading Strategies - Bộ Nội Vụ
Aug Fed Impact: Can X4 Pharmaceuticals Inc stock deliver 10 annual returnsWeekly Stock Recap & AI Based Buy/Sell Signal Reports - Bộ Nội Vụ
p-Chip Corporation, Choice One Rx, and RxERP Launch Precedent-Setting Trial Demonstrating Digital Traceability of Drug Supply Chains and Chain-of-Identity for DSCSA Compliance, Co-Sponsored by Avantor - Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy - Yahoo Finance
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - BioSpace
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage - Yahoo Finance
Why X4 Pharmaceuticals Inc. stock remains resilientQuarterly Risk Review & Daily Oversold Stock Bounce Ideas - ulpravda.ru
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March - Stocktwits
Mirum Pharmaceuticals begins Phase 2 trial for Fragile X syndrome drug By Investing.com - Investing.com South Africa
Why X4 Pharmaceuticals Inc. (48Q0) stock fits value portfoliosJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - Улправда
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Can X4 Pharmaceuticals Inc. stock deliver sustainable ROEInsider Selling Patterns & Investment Risk Management Tips - Улправда
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of “Hold” by Analysts - Defense World
Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Analysts - MarketBeat
What drives X4 Pharmaceuticals Inc 48Q0 stock priceAnalyst Upgrades & Free Powerful Profit Generation - earlytimes.in
Torrent Pharma board gives nod to Rs 12,500-crore bond issue - TradingView — Track All Markets
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Prescription Drug Costs - Britannica
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
What drives X4 Pharmaceuticals Inc stock pricePrice Momentum Alerts & Free Trading Signals to Sharpen Your Edge - earlytimes.in
4,485 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Calamos Advisors LLC - MarketBeat
More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals
Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Grows By 27.1% - Defense World
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PR Newswire
Short Covering: Why X4 Pharmaceuticals Inc 48Q0 stock is a strong buy callJuly 2025 Analyst Calls & Risk Controlled Daily Trade Plans - moha.gov.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript - MSN
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Cwm LLC - MarketBeat
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC - MarketBeat
174,077 Shares in Crinetics Pharmaceuticals, Inc. $CRNX Purchased by Rice Hall James & Associates LLC - MarketBeat
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):